Business
Faron Licenses Traumakine Rights to Pharmbio Korea
Faron Licenses Traumakine Rights to Pharmbio Korea.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 9003A Faron Pharmaceuticals Oy 13 June 2016 \n\nFaron Pharmaceuticals Ltd\n(\"Faron\" or the \"Company\")\n \nFaron Licenses Traumakine® Korean Rights to Pharmbio Korea Inc. (\"Pharmbio\")\n \nTURKU - FINLAND 13 June 2016 - Faron Pharmaceuticals Ltd (LON: FARN), the clinical stage biopharmaceutical company, announces today that it has entered into a licensing agreement with Pharmbio Korea Inc., for the development and commercialisation of Traumakine® in Korea. Pharmbio is based in Seoul and specialises in hospital sales of novel pharmaceutical products. Traumakine is in development for the treatment of Acute Respiratory Distress Syndrome (ARDS), a rare, severe, life threatening medical condition for which there is currently no approved pharmaceutical treatment. Traumakine is now in the pivotal pan-European Phase III INTEREST trial. \nUnder the terms of the agreement Pharmbio will obtain exclusive Korean rights to Traumakine. Faron will receive an initial signing fee of €750,000, which will be recorded as a revenue in H1-2016 financial results, and is entitled to receive additional, undisclosed development based milestones. In addition, Pharmbio will pay Faron one third of Traumakine profits, representing a double digit royalty on net sales, depending on end user pricing, and has agreed to cover development costs for Traumakine in Korea. Additionally, Faron will provide European approval material for Pharmbio to obtain market authorisation in Korea and will also supply Traumakine drug product to Pharmbio at an agreed transfer price.\nDr. Markku Jalkanen, CEO of Faron, said: \"We are very pleased to have signed this agreement with Pharmbio which represents a great opportunity for Traumakine to enter the Korean market. Given the successful track record of Pharmbio sales team, achieving a steady 30% sales growth over the last five years, it is an excellent partner for Traumakine in the Korean market. This licensing deal follows our growth strategy to partner Traumakine in territories where Faron has limited presence, while maintaining rights in major territories including Europe and North America. We believe this agreement represents the best way to accelerate the development of Traumakine and create long term value for our shareholders.\"\nDr. Junsang Nam, CEO of Pharmbio, said: \"We are very excit...